Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Gerald H. Sokol"'
Autor:
Kelly Elleson, Gerald H. Sokol, Weihong Sun, Junmin Whiting, Marie C. Lee, Brian J. Czerniecki, Loretta Loftus
Publikováno v:
Cancer Research. 83:P1-05
BACKGROUND: Studies have consistently demonstrated that breast cancers arise in the left breast more often than the right breast, but no factors have been able to account for this. Some studies have shown age younger than 45 years and late age at men
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4333e54c2aae068692afc39a1021505
https://doi.org/10.1158/1538-7445.sabcs22-p1-05-29
https://doi.org/10.1158/1538-7445.sabcs22-p1-05-29
Autor:
Benjamin A. Gartrell, Alexander G Vandell, Gerald H. Sokol, Mack Roach, Wen-Tien Chen, G. Del Priore, Avi S. Retter, Howard I. Scher
Publikováno v:
Annals of Oncology. 30:v342
Background Androgen deprivation therapy (ADT) is standard treatment for rising PSA with/without circulating tumor cells (CTCs) but adverse events (AEs) limit patient acceptance. We report results of SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN])
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab447710d7a8ac556dc0bc3fb4d89e78
https://doi.org/10.1093/annonc/mdz248.030
https://doi.org/10.1093/annonc/mdz248.030
Autor:
Benjamin A. Gartrell, Giuseppe Del Priore, Gerald H. Sokol, Avi S. Retter, Alexander G Vandell, Mack Roach
Publikováno v:
Journal of Clinical Oncology. 37:79-79
79 Background: Treatment for rising PSA non-metastatic prostate cancer (nmPC) includes multifaceted hormone therapies (HT) associated with increasing related toxicity; in aggregate the risk benefit ratio is not ideal. We report on the use before HT,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea7e07e7250c9ee85e7e3ab4c0f6d6c4
https://doi.org/10.1200/jco.2019.37.7_suppl.79
https://doi.org/10.1200/jco.2019.37.7_suppl.79
Autor:
Wen-Tien Chen, Gerald H. Sokol, Alexander G Vandell, Mack Roach, Benjamin A. Gartrell, Avi S. Retter, Giuseppe Del Priore
Publikováno v:
Journal of Clinical Oncology. 37:83-83
83 Background: Absolute PSA change is an imperfect surrogate of clinical benefit; CTCs and PSA doubling time (DT) may also be used as a surrogate of progression (PD). Hormone therapy (HT) often leads to a rapid decline in PSA, however non-HT may be e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9a261437629c65752701b021ec51c7c
https://doi.org/10.1200/jco.2019.37.7_suppl.83
https://doi.org/10.1200/jco.2019.37.7_suppl.83
Publikováno v:
Journal of Clinical Oncology. 37:277-277
277 Background: SM88 is an oral tyrosine isomer ( TI) and repurposed drugs (CYP3a4 inducer, mTOR inhibitor, oxidative stress catalyst). This regimen has reported no drug related grade 3, 4 or 5 adverse events (JCO 2013 31: e22095) and potential clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b9b1a87217a348d2341c974acbafef1
https://doi.org/10.1200/jco.2019.37.4_suppl.277
https://doi.org/10.1200/jco.2019.37.4_suppl.277
Publikováno v:
Journal of Clinical Oncology. 36:TPS4156-TPS4156
TPS4156Background: Treatment options for recurrent/refractory advanced pancreatic cancer (PC) include largely ineffective toxic therapies or palliation. SM-88 is a combination of dysfunctional tyro...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::464a0893e7f7c0cde07eba7dd7b9d938
https://doi.org/10.1200/jco.2018.36.15_suppl.tps4156
https://doi.org/10.1200/jco.2018.36.15_suppl.tps4156
Autor:
Xinhua Zhu, Patricia Zawisny, Maria Loushin, Marcus Smith Noel, Giuseppe Del Priore, Gerald H. Sokol, Zachary Gostout, Douglas Decorato
Publikováno v:
Journal of Clinical Oncology. 36:e13100-e13100
e13100Background: SM-88 is a relatively non-toxic novel combination therapy (dysfunctional tyrosine, CYP3a4 inducer, mTOR inhibitor and oxidative stress catalyst) that has demonstrated efficacy in ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b31cf4d109e3c36f7c0ee4884347e1
https://doi.org/10.1200/jco.2018.36.15_suppl.e13100
https://doi.org/10.1200/jco.2018.36.15_suppl.e13100
Autor:
Giuseppe Del Priore, Zachary Gostout, Patricia Zawisny, Steve Hoffman, Gerald H. Sokol, Mack Roach, Avi S. Retter
Publikováno v:
Journal of Clinical Oncology. 36:175-175
175 Background: Despite toxicity and no clear survival benefit, non-metastatic recurrent prostate cancer (nmPC) is typically treated with androgen deprivation therapy (ADT). SM88 is a relatively non-toxic novel combination therapy (amino acid analogu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f86299dc68ccf8c9c6d47388afe3272c
https://doi.org/10.1200/jco.2018.36.6_suppl.175
https://doi.org/10.1200/jco.2018.36.6_suppl.175
Autor:
William U. Shipley, Howard M. Sandler, Paul F. Schellhammer, Howard D. Thames, Gerald H. Sokol, Gerald E. Hanks, Mack Roach
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 65:965-974
In 1996 the American Society for Therapeutic Radiology and Oncology (ASTRO) sponsored a Consensus Conference to establish a definition of biochemical failure after external beam radiotherapy (EBRT). The ASTRO definition defined prostate specific anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb523f6159adca6403b0ba457ec4a43
https://doi.org/10.1016/j.ijrobp.2006.04.029
https://doi.org/10.1016/j.ijrobp.2006.04.029
Autor:
Gerald H. Sokol, Alison Martin, Martin H. Cohen, Amna Ibrahim, Richard Pazdur, Nancy S. Scher, Ramzi Dagher, Grant A. Williams, Donna Griebel
Publikováno v:
The Oncologist. 7:393-400
The purpose of this report is to summarize information on drugs recently approved by the U.S. Food and Drug Administration. Three drugs have recently been approved: Gleevec™ (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36128623d76541fb89740bf4d3fe089
https://doi.org/10.1634/theoncologist.7-5-393
https://doi.org/10.1634/theoncologist.7-5-393